Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could anktiva help long COVID sufferers? new trial launches

NCT ID NCT07123727

First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 39 times

Summary

This study tests a drug called Anktiva (NAI) in 40 adults with Long COVID—symptoms that stick around after a COVID infection clears. The main goal is to see if the drug is safe, and researchers will also check if it helps reduce symptoms. Participants must be between 18 and 70 and have had a confirmed COVID infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chan Soon-Schiong Institute for Medicine (CSSIFM)

    RECRUITING

    El Segundo, California, 90245, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.